<DOC>
	<DOCNO>NCT00978224</DOCNO>
	<brief_summary>The purpose study determine whether Viusid administration improve malnutrition , atherosclerosis , erythropoietin response frequency infection episodes subject Chronic Inflammatory Syndrome hemodialysis treatment . The duration double-blind placebo control phase 3 clinical trial 60 week . All patient enrol study receive standard treatment Chronic Inflammatory Syndrome include hemodialysis administration hypercaloric hyperproteic diet . Efficacy assessment carry 12 week end Viusid placebo treatment .</brief_summary>
	<brief_title>Viusid Administration Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>Subjects chronic terminal nephropathy hemodialysis treatment least 3 month Signed informed consent Patients chronic terminal nephropathy previously treat peritoneal dialysis Receptors renal graft Patients malignant neoplastic condition Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>dietary supplement</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>Chronic Inflammatory Syndrome</keyword>
	<keyword>Viusid</keyword>
</DOC>